Innoplexus

Partex.AI is described as an AI-powered therapeutic asset accelerator that uses Big Data and Generative AI to address inefficiencies in drug discovery and development. The product is intended for the life science industry, specifically organizations involved in drug development, including those dealing with in-licensing and out-licensing of therapeutic assets. Its key capabilities include identifying late-stage preclinical to early clinical drug assets that have strong scientific foundations but suboptimal development paths. Partex.AI’s proprietary models then optimize these therapeutics toward key value inflection points. The platform applies AI at scale, validated by wet-lab and Real-World Data, to unlock hidden value in already discovered therapeutic assets. The source text notes that Partex.AI is currently incubating three drug assets in oncology. The product aims to empower faster, more cost-effective, and more targeted drug development by leveraging unrivalled computing power, an AI-first approach, a multi-disciplinary team, and holistic datasets.